abbvie stock forecast 2030

I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. Payout ratios above 75% are not desirable because they may not be sustainable. Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. Note that analysts ABBV stock forecasts can be wrong. One share of ABBV stock can currently be purchased for approximately $156.06. Please disable your ad-blocker and refresh. Abbvie Stock Forecast: up to 179.050 USD! - Walletinvestor.com AbbVie's stock is owned by many different institutional and retail investors. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The median. $163.64. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. Real-time analyst ratings, insider transactions, earnings data, and more. Refer to our. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. How often does AbbVie pay dividends? Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. As such I have modelled similar, although I have included an additional revenue stream from new products which I expect to be minor in nature but ultimately contributing an additional $1.5bn to the top line. call (03) 8658 0539 support.au@capital.com. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. A Warner Bros. Compare Top Brokerages Here. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. . The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. AbbVie's Dividend and Valuation. ABBV has several positive factors pushing its price performance. What is the dividend yield for AbbVie? Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. First of all, as shown in the table above I forecast product sales out to 2030. (my tables). And it couldnt be more wrong! Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. Read our dividend analysis for ABBV. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. contact@marketbeat.com The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. AbbVie saw a increase in short interest in February. Is AbbVie Stock A Buy Or A Sell With Humira Rivals Looming? Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. You should consider whether you understand how CFDs work and can afford the risks. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. Your current $100 investment may be up to $188.28 in 2028. Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. Most stock quote data provided by BATS. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. AbbVie - ABBV Stock Forecast, Price & News - MarketBeat (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. Export data to Excel for your own analysis. The total revenue in 2021 was $56.20 billion with a 31% operating margin. The company is focused on research and has a number of collaborations and partnerships to that end. Rinvoq's progress has been a little more circumspect, but almost as impressive. View the best growth stocks for 2023 here. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. As such, forecasting stock prices is more of an art than a science. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. If you have an ad-blocker enabled you may be blocked from proceeding. I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. For the next nine years, the forecast is for Revenue to grow by 3.57%. First we can take a quick look at what a forward income statement for AbbVie might look like to 2030. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. On average, analysts rate AbbVie stock as a buy. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. Their ABBV share price forecasts range from $140.00 to $200.00. AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. RHHBY vs. ABBV: Which Stock Is the Better Value Option? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. I wrote this article myself, and it expresses my own opinions. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. AbbVie could be the biggest global Pharma by revenue generation in 2028. (844) 978-6257. With a 5-year investment, the revenue is expected to be around +88.28%. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12.